The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins

Pharmaceutical Research

Volumn 13, Issue 2, 1996, Pages 256-264

  Okimoto, Kazuto ^a,b   Rajewski, Roger A ^a   Uekama, Kaneto ^c   Jona, Janan A ^a,d   Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b ASTELLAS PHARMA INC   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Cygnus Therapeutic Systems   (United States)

Author keywords

Charge effects; Cyclodextrins; HP CD; Inclusion complexes; SBE7 CD

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CINNARIZINE; CYCLODEXTRIN; INDOMETACIN; MICONAZOLE; NAPROXEN; PAPAVERINE; TIABENDAZOLE; WARFARIN;

BINDING AFFINITY; COMPLEX FORMATION; DISSOCIATION CONSTANT; DRUG BINDING; DRUG SOLUBILITY; IONIC STRENGTH; PRIORITY JOURNAL; SHORT SURVEY; STOICHIOMETRY;

ANIONS; BETA-CYCLODEXTRINS; CARBOHYDRATE SEQUENCE; CHEMISTRY, PHYSICAL; CYCLODEXTRINS; DRUG INTERACTIONS; KINETICS; MOLECULAR SEQUENCE DATA; SOLUBILITY;

EID: 0030053698     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016047215907     Document Type: Short Survey

References (29)

1. R. A. Rajewski. Development and evaluation of the usefulness and parenteral safety of modified cyclodextrins, Ph.D. dissertation to the University of Kansas, 1990.
2. R. J. Tait, D. J. Skanchy, D. O. Thompson, N. C. Chetwyn, D. A. Dunshee, R. A. Rajewski, V. J. Stella and J. F. Stobaugh. Characterization of sulphoalkyl ether derivatives of β-cyclodextrin by capillary electrophoresis with indirect UV detection. J. Pharm. Biomed. Anal. 9:615-622 (1992).
3. V. J. Stella and R. A. Rajewski. Derivatives of Cyclodextrins Exhibiting Enhanced Aqueous Solubility and the Pharmaceutical Use Thereof. U.S. Patent 5,134,127, July 18, 1992.
4. K. A. Connors and J. M. Lipari. Effect of cycloamyloses on apparent dissociation constants of carboxylic acids and phenols: Equilibrium analytical selectivity induced by complex formation. J. Pharm. Sci. 65:379-383 (1976).
5. K. A. Connors, S-F. Lin and A. B. Wong. Potentiometric study of molecular complexes of weak acids and bases applied to complexes of α-cyclodextrin with para-substituted benzoic acids. J. Pharm. Sci. 71:217-222 (1982).
6. K. A. Connors and T. W. Rosanske. trans-Cinnamic acid-α-cyclodextrin system as studied by solubility, spectral, and potentiometric techniques. J. Pharm. Sci. 69:173-179 (1980).
7. T. Backensfeld, B. W. Müller and K. Kolter. Interaction with cyclodextrins and hydroxypropyl cyclodextrin derivatives. Int. J. Pharm. 74:85-93 (1991).
8. M. Pedersen, M. Edelsten, V. F. Nielsen, A. Scarpellini, S. Skytte and C. Slot. Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole. Int. J. Pharm. 90:247-254 (1993).
9. F-Y. Liu, D. O. Kildsig and A. K. Mitra. Cyclodextrin/weak-electrolyte complexation: Interpretation and estimation of association constants from phase solubility data. Pharm. Res. 9:1671-1672 (1992).
10. A. Y. Tinwalla, B. L. Hoesterey, T-X. Xiang, K. Lim and B. D. Anderson. Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm. Res. 10:1136-1143 (1993).
11. M. D. Johnson, B. L. Hoesterey and B. D. Anderson. Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. J. Pharm. Sci. 83:1142-1146 (1994).
12. T. Järvinen, K. Järvinen, N. Schwarting and V. J. Stella. β-Cyclodextrin derivatives SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J. Pharm. Sci. 84:295-299 (1995).
13. J. L. Mesens, P. Putteman and Verheyen. Pharmaceutical applications of 2-hydroxypropyl-β-cyclodextrin. In D. Duchêne (ed.), New Trends in Cyclodextrins and Derivatives, Editions de Santé, Paris, 369-407, 1991.
14. M. E. Brewster, J. W. Simpkins, M. S. Hora, W. C. Stem and N. Bodor. The potential use of cyclodextrins in parenteral formulations. J. Parent. Sci. Tech. 43:231-240 (1989).
15. R. A. Rajewski, G. Traiger, J. Bresnahan, P. Jaberaboansari, V. J. Stella and D. O. Thompson. Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J. Pharm. Sci. 84:927-932 (1995).
16. K. Shiotani, K. Uehata, T. Irie, K. Uekama, D. O. Thompson and V. J. Stella. Differential effects of sulfate and sulfobutyl ether of β-cyclodextrin on erythrocyte membranes In Vitro. Pharm. Res. 12:78-84 (1995).
17. J. Pitha and J. Pitha. Amorphous water-soluble derivatives of cyclodextrins: Nontoxic dissolution enhancing excipients. J. Pharm. Sci. 74:987-990 (1985).
18. V. J. Stella, H. Y. Lee and D. O. Thompson. The effect of SBE4-β-CD on I.V. methylprednisolone pharmacokinetics in rats: Comparison to a co-solvent solution and two water soluble prodrugs. Int. J. Pharm. 120:189-195 (1995).
19. V. J. Stella, H. Y. Lee and D. O. Thompson. The effect of SBE4-β-CD on I.M. prednisolone pharmacokinetics and tissue damage in rabbits: Comparison to a co-solvent solution and a water soluble prodrug. Int. J. Pharm. 120:197-204 (1995).
20. T. Järvinen, K. Järvinen, D. O. Thompson and V. J. Stella. The effect of a modified β-Cyclodextrin, SBE4-β-CD, on the aqueous stability and ocular absorption of pilocarpine. Cur. Eye Res. 13:897-905 (1994).
21. T. Järvinen, K. Järvinen, A. K. Ami, D. O. Thompson and V. J. Stella. Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J. Ocul. Pharmacol. Ther. 11:95-106 (1995).
22. 6-benzylguanine (NSC-637037) in aqueous solutions. Int. J. Pharm. 125:55-61 (1995).
23. M. Pedersen, S. Pedersen and A.M. Sørensen. Polymorphism of miconazole during preparation of solid systems of the drug and β-cyclodextrin. Pharm. Acta Helv. 68:43-47 (1993).
24. T. Higuchi and K. Connors. Phase-solubility techniques. Adv. Anal. Inst. 4:117-212 (1965).
25. K. G. Mooney, M. A. Mintun, K. J. Himmelstein and V. J. Stella. Dissolution kinetics of carboxylic acids I: Effect of pH under unbuffered conditions. J. Pharm. Sci. 70:13-22 (1981).
26. R. Krishnamoorthy, A. Wolka and A. K. Mitra. Complexation of weak bases with cyclodextrins: Estimation and interpretation of association constants from phase solubility diagrams. Pharm. Res. 10:S-263 (1993).
27. F. Djedaïni, S. Z. Lin, B. Perly and D. Wouessidjewe. High field NMR techniques of a β-cyclodextrin-indomethacin inclusion complex. J. Pharm. Sci. 79:643-646 (1990).
28. S-Z. Lin, D. Wouessidjewe, M-C. Poelman, D. Duchêne. Indomethacin and cyclodextrin complexes. Int. J. Pharm. 69:211-219 (1991).
29. T. Tokumura, H. Ueda, Y. Tsushima, M. Kasai, M. Kayano, I. Amada and T. Nagai. Inclusion complexes of cinnarizine with β-cyclodextrin in aqueous solution and in the solid state. Chem. Pharm. Bull. 32:4179-4184 (1984).